These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23328224)

  • 41. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
    Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
    N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma.
    Bateman ED; Kornmann O; Schmidt P; Pivovarova A; Engel M; Fabbri LM
    J Allergy Clin Immunol; 2011 Aug; 128(2):315-22. PubMed ID: 21807250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of formoterol and tiotropium bromide on mucus clearance in patients with COPD.
    Meyer T; Reitmeir P; Brand P; Herpich C; Sommerer K; Schulze A; Scheuch G; Newman S
    Respir Med; 2011 Jun; 105(6):900-6. PubMed ID: 21397483
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study.
    Vogelmeier C; Kardos P; Harari S; Gans SJ; Stenglein S; Thirlwell J
    Respir Med; 2008 Nov; 102(11):1511-20. PubMed ID: 18804362
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tiotropium in COPD patients not previously receiving maintenance respiratory medications.
    Adams SG; Anzueto A; Briggs DD; Menjoge SS; Kesten S
    Respir Med; 2006 Sep; 100(9):1495-503. PubMed ID: 16698259
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhaled anticholinergic drugs and risk of acute urinary retention.
    Afonso AS; Verhamme KM; Stricker BH; Sturkenboom MC; Brusselle GG
    BJU Int; 2011 Apr; 107(8):1265-72. PubMed ID: 20880196
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium.
    O'Connor AB
    Ann Intern Med; 2006 Jan; 144(2):148; author reply 148-9. PubMed ID: 16418423
    [No Abstract]   [Full Text] [Related]  

  • 48. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD.
    Tashkin DP; Donohue JF; Mahler DA; Huang H; Goodwin E; Schaefer K; Hanrahan JP; Andrews WT
    Respir Med; 2009 Apr; 103(4):516-24. PubMed ID: 19208459
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
    Tashkin DP; Celli B; Senn S; Burkhart D; Kesten S; Menjoge S; Decramer M;
    N Engl J Med; 2008 Oct; 359(15):1543-54. PubMed ID: 18836213
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium.
    Good CB; Longo L
    Ann Intern Med; 2006 Jan; 144(2):147; author reply 148-9. PubMed ID: 16418422
    [No Abstract]   [Full Text] [Related]  

  • 51. Long-term bronchodilator inhaled therapy in COPD: the role of tiotropium bromidum.
    Antoniu SA
    Rev Recent Clin Trials; 2009 May; 4(2):89-98. PubMed ID: 19463105
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tiotropium: an inhaled anticholinergic for chronic obstructive pulmonary disease.
    Olin JL
    Am J Health Syst Pharm; 2005 Jun; 62(12):1263-9. PubMed ID: 15947126
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials.
    Haney S; Hancox RJ
    Respir Res; 2007 Mar; 8(1):19. PubMed ID: 17341317
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma.
    O'Connor BJ; Towse LJ; Barnes PJ
    Am J Respir Crit Care Med; 1996 Oct; 154(4 Pt 1):876-80. PubMed ID: 8887578
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-acting anticholinergics in the treatment of asthma.
    Guyer AC; Long AA
    Curr Opin Allergy Clin Immunol; 2013 Aug; 13(4):392-8. PubMed ID: 23756872
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease.
    Joos GF
    Expert Opin Investig Drugs; 2010 Feb; 19(2):257-64. PubMed ID: 20047505
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease.
    McCrory DC; Brown CD
    Cochrane Database Syst Rev; 2002; 2003(4):CD003900. PubMed ID: 12519615
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Republished: pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications.
    Singh S; Loke YK; Enright P; Furberg CD
    Postgrad Med J; 2014 Apr; 90(1062):205-7. PubMed ID: 24643260
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The pharmacological rationale for the use of inhaled tiotropium in asthma.
    Popescu FD
    Pneumologia; 2015; 64(1):52-3. PubMed ID: 26016057
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sequential comparison of tiotropium to high-dose ipratropium in patients with chronic obstructive pulmonary disease in a practice setting.
    Gauhar U; Dransfield M; Cooper JA
    Int J Chron Obstruct Pulmon Dis; 2009; 4():391-5. PubMed ID: 19888357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.